Rationale and design of ENDEAVOR: A sequential phase 2b-3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction.

Lund LH, Lam CSP, Pizzato PE, Gabrielsen A, Michaëlsson E, Nelander K, Ericsson H, Holden J, Folkvaljon F, Mattsson A, Collén A, Aurell M, Whatling C, Baldus S, Drelich G, Goudev A, Merkely B, Bergh N, Shah SJ

Open source

DOI: 10.1002/ejhf.2977
Published: 2023 Sep
Container: European journal of heart failure
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/ejhf.2977,
  title = {Rationale and design of ENDEAVOR: A sequential phase 2b-3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction.},
  author = {Lund LH and Lam CSP and Pizzato PE and Gabrielsen A and Michaëlsson E and Nelander K and Ericsson H and Holden J and Folkvaljon F and Mattsson A and Collén A and Aurell M and Whatling C and Baldus S and Drelich G and Goudev A and Merkely B and Bergh N and Shah SJ},
  year = {2023},
  journal = {European journal of heart failure},
  doi = {10.1002/ejhf.2977},
  url = {https://doi.org/10.1002/ejhf.2977}
}

RIS

TY  - JOUR
TI  - Rationale and design of ENDEAVOR: A sequential phase 2b-3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction.
AU  - Lund LH
AU  - Lam CSP
AU  - Pizzato PE
AU  - Gabrielsen A
AU  - Michaëlsson E
AU  - Nelander K
AU  - Ericsson H
AU  - Holden J
AU  - Folkvaljon F
AU  - Mattsson A
AU  - Collén A
AU  - Aurell M
AU  - Whatling C
AU  - Baldus S
AU  - Drelich G
AU  - Goudev A
AU  - Merkely B
AU  - Bergh N
AU  - Shah SJ
PY  - 2023
JO  - European journal of heart failure
DO  - 10.1002/ejhf.2977
UR  - https://doi.org/10.1002/ejhf.2977
ER  -

APA

LH, L., CSP, L., PE, P., A, G., E, M., K, N., H, E., J, H., F, F., A, M., A, C., M, A., C, W., S, B., G, D., A, G., B, M., N, B., & SJ, S. (2023). Rationale and design of ENDEAVOR: A sequential phase 2b-3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction.. European journal of heart failure. https://doi.org/10.1002/ejhf.2977

Source records

pubmed · retrieved 2026-09-27T06:38:53.021Z